14634例肝癌不同肿瘤大小的预后分析

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES European Journal of Cancer Care Pub Date : 2023-05-22 DOI:10.1155/2023/1106975
Zilin Chen, Hexin Zheng, Wenshuai Zeng, Meng-Lu Liu, Yong Chen
{"title":"14634例肝癌不同肿瘤大小的预后分析","authors":"Zilin Chen, Hexin Zheng, Wenshuai Zeng, Meng-Lu Liu, Yong Chen","doi":"10.1155/2023/1106975","DOIUrl":null,"url":null,"abstract":"Aim. This study investigated the effect of tumor size and other factors on the survival and prognosis of hepatocellular carcinoma (HCC). Methods. All HCC populations based on the National Cancer Institute’s SEER database to receive from 2010 to 2016 were employed in the study. Results. This study enrolled a total of 14,634 HCC. Among them, 1,686 patients had tumors ≤ 2 cm, 6,169 patients had tumors 2–5 cm, and 6,779 patients had tumors > 5 cm. The results using univariate analysis showed that all factors were significant prognostic factors for overall survival and specific survival. Patients with tumor size ≤ 2 cm were more likely to survive, while patients with tumor size > 5 cm had a lower survival rate. Patients who had surgery or surgery plus chemotherapy had a higher chance of survival in stages I-II, and the survival rate declined smoothly during the 80 months. The change rate of the mortality rate increased rapidly during the period of 1–12 cm; afterwards, the mortality rate’s HR was basically and smoothly maintained at a high level. Conclusions. Tumor size was positively correlated with the mortality rate of HCC. Survival rates were greater in patients with tumors ≤ 2 cm who underwent surgery or surgery plus chemotherapy. Patients with HCC in the early stage had a higher survival probability particularly when they had experienced surgery or surgery plus chemotherapy.","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"1 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients\",\"authors\":\"Zilin Chen, Hexin Zheng, Wenshuai Zeng, Meng-Lu Liu, Yong Chen\",\"doi\":\"10.1155/2023/1106975\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim. This study investigated the effect of tumor size and other factors on the survival and prognosis of hepatocellular carcinoma (HCC). Methods. All HCC populations based on the National Cancer Institute’s SEER database to receive from 2010 to 2016 were employed in the study. Results. This study enrolled a total of 14,634 HCC. Among them, 1,686 patients had tumors ≤ 2 cm, 6,169 patients had tumors 2–5 cm, and 6,779 patients had tumors > 5 cm. The results using univariate analysis showed that all factors were significant prognostic factors for overall survival and specific survival. Patients with tumor size ≤ 2 cm were more likely to survive, while patients with tumor size > 5 cm had a lower survival rate. Patients who had surgery or surgery plus chemotherapy had a higher chance of survival in stages I-II, and the survival rate declined smoothly during the 80 months. The change rate of the mortality rate increased rapidly during the period of 1–12 cm; afterwards, the mortality rate’s HR was basically and smoothly maintained at a high level. Conclusions. Tumor size was positively correlated with the mortality rate of HCC. Survival rates were greater in patients with tumors ≤ 2 cm who underwent surgery or surgery plus chemotherapy. Patients with HCC in the early stage had a higher survival probability particularly when they had experienced surgery or surgery plus chemotherapy.\",\"PeriodicalId\":11953,\"journal\":{\"name\":\"European Journal of Cancer Care\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/1106975\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/1106975","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

的目标。本研究探讨肿瘤大小等因素对肝细胞癌(HCC)生存及预后的影响。方法。该研究采用了2010年至2016年美国国家癌症研究所SEER数据库中接收的所有HCC人群。结果。本研究共纳入14634例HCC患者。其中肿瘤≤2 cm的有1686例,肿瘤2 ~ 5 cm的有6169例,肿瘤bb0 ~ 5 cm的有6779例。单因素分析结果显示,所有因素均为影响总生存期和特异性生存期的重要预后因素。肿瘤大小≤2 cm的患者生存率较高,而肿瘤大小为bbb50 cm的患者生存率较低。接受手术或手术加化疗的患者在I-II期的生存率更高,在80个月的时间里生存率平稳下降。1 ~ 12 cm期间死亡率变化率迅速增大;此后,死亡率的HR基本平稳地维持在较高水平。结论。肿瘤大小与HCC死亡率呈正相关。肿瘤≤2 cm的患者接受手术或手术加化疗的生存率更高。早期HCC患者有较高的生存率,特别是当他们经历过手术或手术加化疗时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients
Aim. This study investigated the effect of tumor size and other factors on the survival and prognosis of hepatocellular carcinoma (HCC). Methods. All HCC populations based on the National Cancer Institute’s SEER database to receive from 2010 to 2016 were employed in the study. Results. This study enrolled a total of 14,634 HCC. Among them, 1,686 patients had tumors ≤ 2 cm, 6,169 patients had tumors 2–5 cm, and 6,779 patients had tumors > 5 cm. The results using univariate analysis showed that all factors were significant prognostic factors for overall survival and specific survival. Patients with tumor size ≤ 2 cm were more likely to survive, while patients with tumor size > 5 cm had a lower survival rate. Patients who had surgery or surgery plus chemotherapy had a higher chance of survival in stages I-II, and the survival rate declined smoothly during the 80 months. The change rate of the mortality rate increased rapidly during the period of 1–12 cm; afterwards, the mortality rate’s HR was basically and smoothly maintained at a high level. Conclusions. Tumor size was positively correlated with the mortality rate of HCC. Survival rates were greater in patients with tumors ≤ 2 cm who underwent surgery or surgery plus chemotherapy. Patients with HCC in the early stage had a higher survival probability particularly when they had experienced surgery or surgery plus chemotherapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Journal of Cancer Care
European Journal of Cancer Care 医学-康复医学
CiteScore
4.00
自引率
4.80%
发文量
213
审稿时长
3 months
期刊介绍: The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: - Primary, secondary and tertiary care for cancer patients - Multidisciplinary and service-user involvement in cancer care - Rehabilitation, supportive, palliative and end of life care for cancer patients - Policy, service development and healthcare evaluation in cancer care - Psychosocial interventions for patients and family members - International perspectives on cancer care
期刊最新文献
Comparison of Nobiletin and 5-Demethylnobiletin as Cancer Chemopreventive Agents The Relationship Between Upper-Limb Lymphedema and Fatigue Among Breast Cancer Survivors Development Process of a Holistic Assessment Questionnaire to Measure and Monitor Cancer-Related Fatigue Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study Ferroptosis-Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1